Guidance and quality standards Awaiting development

Showing 31 to 40 of 289

Guidance and quality standards awaiting development
Title	Type
Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550	Technology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]	Technology appraisal guidance
BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis TS ID 12016	Technology appraisal guidance
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]	Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis TS ID 10334	Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991	Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592	Technology appraisal guidance
Botulinum toxin type A for preventing episodic migraine TS ID 11939	Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma TS ID 11987	Technology appraisal guidance
Bupivacaine–meloxicam for treating postoperative pain [ID2728]	Technology appraisal guidance